BDPARP contains Olaparib 150 mg, a targeted therapy used to treat certain types of ovarian, breast, pancreatic, and prostate cancers. It works by blocking PARP enzymes to help stop cancer cells from repairing themselves.
| Composition | Olaparib |
| Manufacturer | BDR |
| Packing | 28 Tablets |
| Prescribed For | Ovarian, Breast, Pancreatic, Prostate cancer |
| Expiry | December 2027 |
Ribaxa contains Olaparib, a targeted PARP inhibitor used in the treatment of certain types of ovarian, breast, prostate, and pancreatic cancers. It works by blocking cancer cell repair pathways, helping slow or stop tumor growth.
| Composition | Olaparib |
| Manufacturer | Dr. Reddy’s |
| Packing | 60 Tablets |
| Prescribed For | Ovarian, Breast, Pancreatic, Prostate cancer |
| Expiry | December 2027 |
Ibyra (Olaparib 150mg Tablets) is a targeted therapy used to treat ovarian, breast, pancreatic, and prostate cancers with BRCA gene mutations. It works by blocking cancer cell repair, slowing their growth.
| Composition | Olaparib |
| Manufacturer | Zydus |
| Packing | 60 Tablets |
| Prescribed For | Ovarian, Breast, Pancreatic, Prostate cancer |
| Expiry | December 2027 |
Bracanat 150 mg Tablet is an oral anticancer medicine containing Olaparib, used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. It works by blocking cancer cell DNA repair, helping slow disease progression.
| Composition | Olaparib |
| Manufacturer | Natco Pharma Ltd |
| Packing | 30 Tablets in 1 bottle |
| Prescribed For | Ovarian and Breast Cancer |
| Expiry | December 2027 |
Olabir 150 mg Tablet is an oral anticancer medication containing Olaparib, a PARP inhibitor used to treat cancers associated with BRCA gene mutations. It is commonly prescribed for ovarian, breast, pancreatic, and prostate cancers, helping to slow cancer progression and improve survival in advanced stages.
| Composition | Olaparib |
| Manufacturer | Aprazer Healthcare Pvt Ltd |
| Packing | 30 Tablets in 1 bottle |
| Prescribed For | Ovarian and Breast Cancer |
| Expiry | December 2027 |
